|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ACE2 |
Gene summary for ACE2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ACE2 | Gene ID | 59272 |
| Gene name | angiotensin converting enzyme 2 | |
| Gene Alias | ACEH | |
| Cytomap | Xp22.2 | |
| Gene Type | protein-coding | GO ID | GO:0001816 | UniProtAcc | Q9BYF1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 59272 | ACE2 | Pat01-B | Human | Stomach | GC | 8.03e-44 | 8.31e-01 | 0.5754 |
| 59272 | ACE2 | Pat03-B | Human | Stomach | GC | 8.66e-31 | 6.63e-01 | 0.3693 |
| 59272 | ACE2 | SIM_1 | Human | Stomach | SIM | 3.46e-03 | 2.45e-01 | 0.3573 |
| 59272 | ACE2 | SIM_4 | Human | Stomach | SIM | 8.17e-07 | 3.36e-01 | 0.2664 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00425938 | Breast | Precancer | glucose homeostasis | 31/1080 | 258/18723 | 8.89e-05 | 1.69e-03 | 31 |
| GO:00335008 | Breast | Precancer | carbohydrate homeostasis | 31/1080 | 259/18723 | 9.56e-05 | 1.79e-03 | 31 |
| GO:00420633 | Breast | Precancer | gliogenesis | 33/1080 | 301/18723 | 3.06e-04 | 4.40e-03 | 33 |
| GO:00100013 | Breast | Precancer | glial cell differentiation | 25/1080 | 225/18723 | 1.29e-03 | 1.37e-02 | 25 |
| GO:00516047 | Breast | Precancer | protein maturation | 28/1080 | 294/18723 | 6.45e-03 | 4.50e-02 | 28 |
| GO:0048708 | Breast | Precancer | astrocyte differentiation | 11/1080 | 81/18723 | 6.65e-03 | 4.57e-02 | 11 |
| GO:0021782 | Breast | Precancer | glial cell development | 14/1080 | 116/18723 | 6.92e-03 | 4.67e-02 | 14 |
| GO:004206311 | Breast | IDC | gliogenesis | 39/1434 | 301/18723 | 8.63e-04 | 1.00e-02 | 39 |
| GO:00100011 | Breast | IDC | glial cell differentiation | 31/1434 | 225/18723 | 1.04e-03 | 1.15e-02 | 31 |
| GO:004259313 | Breast | IDC | glucose homeostasis | 34/1434 | 258/18723 | 1.34e-03 | 1.39e-02 | 34 |
| GO:003350013 | Breast | IDC | carbohydrate homeostasis | 34/1434 | 259/18723 | 1.43e-03 | 1.46e-02 | 34 |
| GO:005160413 | Breast | IDC | protein maturation | 35/1434 | 294/18723 | 6.18e-03 | 4.40e-02 | 35 |
| GO:00420632 | Breast | DCIS | gliogenesis | 39/1390 | 301/18723 | 4.76e-04 | 6.25e-03 | 39 |
| GO:00100012 | Breast | DCIS | glial cell differentiation | 31/1390 | 225/18723 | 6.24e-04 | 7.87e-03 | 31 |
| GO:004259323 | Breast | DCIS | glucose homeostasis | 34/1390 | 258/18723 | 7.87e-04 | 9.11e-03 | 34 |
| GO:003350023 | Breast | DCIS | carbohydrate homeostasis | 34/1390 | 259/18723 | 8.43e-04 | 9.58e-03 | 34 |
| GO:005160422 | Breast | DCIS | protein maturation | 34/1390 | 294/18723 | 6.72e-03 | 4.66e-02 | 34 |
| GO:0033500 | Colorectum | AD | carbohydrate homeostasis | 84/3918 | 259/18723 | 9.10e-06 | 2.15e-04 | 84 |
| GO:0042593 | Colorectum | AD | glucose homeostasis | 83/3918 | 258/18723 | 1.44e-05 | 3.11e-04 | 83 |
| GO:0051604 | Colorectum | AD | protein maturation | 85/3918 | 294/18723 | 6.73e-04 | 6.91e-03 | 85 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ACE2 | SNV | Missense_Mutation | novel | c.1216G>A | p.Glu406Lys | p.E406K | Q9BYF1 | protein_coding | deleterious(0.01) | probably_damaging(0.98) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ACE2 | SNV | Missense_Mutation | c.484N>T | p.Leu162Phe | p.L162F | Q9BYF1 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-D8-A1JG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| ACE2 | insertion | Nonsense_Mutation | novel | c.1544_1545insCTATTGATTGCTGATGACGGGGACAAGATC | p.Tyr516_Thr517insTer | p.Y516_T517ins* | Q9BYF1 | protein_coding | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
| ACE2 | SNV | Missense_Mutation | novel | c.1854C>G | p.Ile618Met | p.I618M | Q9BYF1 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-EK-A2RN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| ACE2 | SNV | Missense_Mutation | novel | c.1371N>C | p.Glu457Asp | p.E457D | Q9BYF1 | protein_coding | tolerated(1) | possibly_damaging(0.536) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| ACE2 | SNV | Missense_Mutation | novel | c.2408C>T | p.Thr803Ile | p.T803I | Q9BYF1 | protein_coding | deleterious_low_confidence(0) | benign(0.388) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ACE2 | SNV | Missense_Mutation | novel | c.1486A>G | p.Thr496Ala | p.T496A | Q9BYF1 | protein_coding | tolerated(0.24) | benign(0.005) | TCGA-ZJ-AB0H-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| ACE2 | SNV | Missense_Mutation | novel | c.1091N>C | p.Val364Ala | p.V364A | Q9BYF1 | protein_coding | deleterious(0) | possibly_damaging(0.502) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ACE2 | SNV | Missense_Mutation | novel | c.2269A>G | p.Ile757Val | p.I757V | Q9BYF1 | protein_coding | tolerated_low_confidence(0.58) | benign(0.01) | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ACE2 | SNV | Missense_Mutation | rs865959788 | c.1010N>A | p.Gly337Glu | p.G337E | Q9BYF1 | protein_coding | tolerated(0.43) | benign(0.023) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 59272 | ACE2 | ENZYME, TRANSPORTER, DRUGGABLE GENOME, NEUTRAL ZINC METALLOPEPTIDASE, CELL SURFACE, PROTEASE | inhibitor | 223366196 | ORE-1001 | |
| 59272 | ACE2 | ENZYME, TRANSPORTER, DRUGGABLE GENOME, NEUTRAL ZINC METALLOPEPTIDASE, CELL SURFACE, PROTEASE | GL1001 | ORE-1001 | ||
| 59272 | ACE2 | ENZYME, TRANSPORTER, DRUGGABLE GENOME, NEUTRAL ZINC METALLOPEPTIDASE, CELL SURFACE, PROTEASE | GSK2586881 | GSK-2586881 | 25893478 | |
| 59272 | ACE2 | ENZYME, TRANSPORTER, DRUGGABLE GENOME, NEUTRAL ZINC METALLOPEPTIDASE, CELL SURFACE, PROTEASE | ORE-1001 | ORE-1001 | ||
| 59272 | ACE2 | ENZYME, TRANSPORTER, DRUGGABLE GENOME, NEUTRAL ZINC METALLOPEPTIDASE, CELL SURFACE, PROTEASE | inhibitor | 178103169 | ||
| 59272 | ACE2 | ENZYME, TRANSPORTER, DRUGGABLE GENOME, NEUTRAL ZINC METALLOPEPTIDASE, CELL SURFACE, PROTEASE | activator | 223366197 | ||
| 59272 | ACE2 | ENZYME, TRANSPORTER, DRUGGABLE GENOME, NEUTRAL ZINC METALLOPEPTIDASE, CELL SURFACE, PROTEASE | LISINOPRIL | LISINOPRIL | ||
| 59272 | ACE2 | ENZYME, TRANSPORTER, DRUGGABLE GENOME, NEUTRAL ZINC METALLOPEPTIDASE, CELL SURFACE, PROTEASE | 178101824 | |||
| 59272 | ACE2 | ENZYME, TRANSPORTER, DRUGGABLE GENOME, NEUTRAL ZINC METALLOPEPTIDASE, CELL SURFACE, PROTEASE | captopril | CAPTOPRIL | 17473847 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |